1997

• Founded as a spin-off from the Idar-Oberstein based Bone Marrow Transplantation Unit

• Granted a first Manufacturing licence from the local authorities for the production of bone marrow and apheresis stem cell products as well as cord blood preparations
• Since then manufacturing and quality control of stem cell products (bone marrow, apheresis, cord blood)

• Manufacturing licence is extended to cover the production of diverse retroviral vectors and genetically modified CD34+ stem cells

• EUFETS becomes a subsidiary of Fresenius Biotech GmbH
• EUFETS decides to build new clean room facility
• Manufacturing licence is extended to cover the production of diverse retroviral vectors and genetically modified T-cells

• EUFETS supports first clinical trial with retroviral vector and allogeneic gene-modified T-cells (suicide gene therapy)
• EUFETS performs first GLP studies

• EUFETS achieves accreditation as Good Laboratory Practice (GLP) facility
• New production facility is inspected and accepted by the local authorities for the production of cell- and gene therapy medicinal products
• EUFETS produces retroviral vector for ADA SCID gene therapy trial in UK

• Manufacturing licence is extended to cover the production of genetically modified HIV+ T-cells as well as several new retroviral vectors
• EUFETS produces study medication for a phase I/II anti HIV gene therapy (autologous T-cell) trial
• EUFETS produces gene-modified autologous stem cells for a phase I/II CGD gene therapy trial
• EUFETS produces retroviral vector for several clinical gene therapy trials in Europe

• New large scale GMP production technique for retroviral vectors and subsequent concentration is established and validated
• Manufacturing licence is extended to cover the new production techniques for retroviral vector production
• EUFETS produces retroviral vector for several clinical gene therapy trials in Europe and Japan